Abstract:To standardize the prevention and clinical management of lung cancer, improve patients' survival outcomes, and offer professional insight for clinicians, the Oncology Society of Chinese Medical Association has summoned experts from departments of pulmonary medicine, oncology, thoracic surgery, radiotherapy, imaging, and pathology to formulate the Oncology Society of Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer in China (2023 edition) through consensus meetings. Updates in this edition include 1) cancer screening: deletion of high-risk traits of lung cancer based on epidemiological investigations in the Caucasian population, while preserving features confirmed by research on the Chinese population. Advice on screening institutions is also added to raise awareness of the merits and demerits of lung cancer screening through detailed illustrations. 2) Principles of histopathologic evaluation: characteristics of four types of neuroendocrine tumors (typical carcinoid, atypical carcinoid, large cell carcinoma, and small cell carcinoma) are reviewed. 3) Surgical intervention: more options of resection are available for certain peripheral lesions based on several clinical studies (CALGB140503, JCOG0802, JCOG1211). 4) neoadjuvant/adjuvant therapy: marked improvement in the prognosis of non-small cell lung cancer (NSCLC) patients receiving neoadjuvant immunotherapy are reviewed; more options for consolidation immunotherapy after radiochemotherapy have also emerged. 5) Targeted and immune therapy: tyrosine kinase inhibitors of sensitive driver mutations such as EGFR and ALK as well as rare targets such as MET exon 14 skipping, RET fusion, ROS1 fusion, and NTRK fusion have been approved, offering more treatment options for clinicians and patients. Furthermore, multiple immune checkpoint inhibitors have been granted for the treatment of NSCLC and SCLC, resulting in prolonged survival of late-stage lung cancer patients. This guideline is established based on the current availability of domestically approved medications, recommendations of international guidelines, and present clinical practice in China as well as integration of the latest medical evidence of pathology, genetic testing, immune molecular biomarker detection, and treatment methods of lung cancer in recent years, to provide recommendations for professionals in clinical oncology, radiology, laboratory, and rehabilitation.

Clinical Practice Guidelines in Breast Cancer by Chinese Anti-Cancer Association (2015 version):interpretation of updates in terms of systemic treatment

Updated Understanding on the National Comprehensive Cancer Network Guidelines (version 1. 2017) for Diagnosis and Treatment of Pancreatic Adenocarcinoma

Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)

Updates and interpretations of the National Comprehensive Cancer Network guidelines for breast cancer (Version 1, 2016)

Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024

Interpretation of NCCN Clinical Practice Guideline for Breast Cancer in 2018

CSCO Guidelines for Colorectal Cancer Version 2024: Updates and Discussions.

Interpretation of“guideline and standard for the diagnosis and treatment of breast cancer by Chinese ;Anti-Cancer Association (2015 edition)”:surgical section

Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China (2021)

[Comprehensive Management Guideline for Breast Cancer Follow-Up and Concomitant Diseases].

[Guidelines for clinical diagnosis and treatment of advanced triple negative breast cancer in China（2024 edition）]

Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Breast Cancer (2020 version)

Chinese Society of Breast Surgery (CSBrS) Practice Guideline 2022

Clinical practice guidelines for neoadjuvant therapy in patients with early-stage breast cancer: Chinese Society of Breast Surgery practice guidelines 2022

Clinical practice guidelines for diagnosis and treatment of invasive breast cancer: Chinese Society of Breast Surgery (CSBrS) practice guidelines 2021

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2023 edition)]

Guidelines on the diagnosis and treatment of breast cancer (2011 edition).

Update in Version 2021 of CSCO Guidelines for Colorectal Cancer from Version 2020

[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]

Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023